3 Incredible Ways Technology Can Help Treat Parkinson’s Disease

How can Apple’s iPhone, Google Glass, and Medtronic’s “brain pacemaker” improve the lives of Parkinson’s patients across the world?

May 4, 2014 at 11:01AM

Parkinson's disease, a progressive disorder of the nervous system, affects up to one million Americans and as many as ten million people worldwide. Approximately 60,000 new patients in America are diagnosed with Parkinson's every year.

Parkinson's disease is characterized by tremors, rigid muscles, slowed movements, slurred speech, and a decrease in involuntary motor functions. There is no cure for Parkinson's, but several drugs -- such as levodopa -- can manage the disease by boosting the brain's supply of dopamine.

Yet in recent years, researchers have discovered that new smart devices -- such as Apple (NASDAQ:AAPL) iPhones, Google (NASDAQ:GOOG)(NASDAQ:GOOGL) Glass, and Medtronic's (NYSE:MDT) "brain pacemakers" -- can help identify and help manage potential symptoms of the disease.

Apple's iPhone can detect Parkinson's symptoms
Apple's iPhone is gaining prominence in medical use for two reasons. First, it's an ultra-portable computer with an onboard camera, motion sensors, and wireless connectivity. Second, its software and hardware configurations are identical across same-generation devices -- making it a simpler platform for app development than the fragmented world of Google Android devices.

In 2011, researchers at UCLA demonstrated how an iPhone's accelerometers could detect tremors in a patient's hand. The patient would wear a glove with the iPhone strapped to the top, and hold out his or her hand to get a reading. A customized app then collected the tremor data and delivered it via email to a physician for interpretation. Later that year, Digital Arts released Tremor-Meter, an iOS app based on the same concepts as the UCLA experiment.


Digital Arts' Tremor-Meter. Source: iTunes.

In 2013, Casa Futura released iParkinsons, an iOS app which detects and corrects changes in speech by improving articulation in patients. It does this by modifying how a user hears his or her own voice through the headphones. Changing the speed, pauses, and volume of a patient's speech increased the intelligibility of speech in subjects by two to six times, according to the company's studies.

Google Glass enters Parkinson's trials
As I mentioned in a previous article, Google Glass could eventually replace the iPhone as the ideal smart medical device for a simple reason -- it offers most of the benefits of the iPhone in a hands-free form that is ideal for medical workers.


Google Glass. Source: Wikimedia Commons.

Therefore, it's not surprising that UK researchers are now studying Google Glass as a potential tool to help Parkinson's patients retain their independence longer. The trial, which is taking place in Newcastle University, uses Glass units donated by Google on volunteers 46 to 70 years of age.

In the study, Glass provides discreet prompts to patients, such as to speak up if their voice is too soft, to swallow at the right time, and to prevent drooling -- which are all associated with the overall slowdown in involuntary motor functions. The motion sensors in Glass can also support patients who experience "freezing" episodes, during which they are unable to move. Glass can even remind patients to take their medication on time -- a major problem with Parkinson's patients due to gradual slowdowns in their daily routines.

Medtronic's "brain pacemaker"
While the iPhone and Glass can help identify and correct for potential symptoms of Parkinson's disease, Medtronic's "brain pacemaker" could be a breakthrough in treating the disease.

Medtronic's Activa Neurostimulator, which is similar to a cardiac pacemaker, is implanted near the collarbone with very thin wires connected to the brain. The Activa Neurostimulator then delivers electric "deep brain stimulation" (DBS) to block certain brain signals which cause disabling motor problems.

A doctor modifies the electrical settings over a course of several sessions to reach the ideal configuration for each patient. According to Medtronic, the Activa Neurostimulator is ideal for patients on which levodopa and other treatments have lost their effectiveness.


Three models of the Activa -- the PC, RC, and SC. Source: Medtronic.

A newer version of the Activa, known as the Activa PC+S, was implanted in the first patient last August. It is the first DBS device which can sense and record brain activity while simultaneously providing targeted DBS therapy. This provides researchers with a more complete view of how the brain responds to DBS treatment, which could possibly lead to the development of a real-time closed loop -- in which a device intelligently modifies its electrical flow for certain conditions without physician assistance.

The Foolish takeaway
In closing, companies focusing on pharmaceutical treatments for Parkinson's disease only represent half of the big picture. We should realize just how much smart devices like Apple's iPhone, Google Glass, and Medtronic's brain pacemakers could also improve patients' lives in the future.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Leo Sun owns shares of Apple and Google (C shares). The Motley Fool recommends Apple, Google (A shares), and Google (C shares). The Motley Fool owns shares of Apple, Google (A shares), Google (C shares), and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information